Showing 1 - 9 of 9
Persistent link: https://www.econbiz.de/10008751992
A robust body of literature spanning several countries indicates a positive association between maternal employment and child body mass index (BMI). Fewer studies have examined the role of paternal employment. More importantly, little empirical work examines the mechanisms that might explain the...
Persistent link: https://www.econbiz.de/10010702822
Persistent link: https://www.econbiz.de/10008646200
The National Institute for Health and Clinical Excellence (NICE) invited the manufacturer of dronedarone (Multaq®, Sanofi-Aventis Limited, UK) to submit evidence on the clinical and cost effectiveness of the anti-arrhythmic drug (AAD) for the treatment of atrial fibrillation (AF) and atrial...
Persistent link: https://www.econbiz.de/10011001685
Following a licence extension to include those aged 6–11 years, the National Institute for Health and Clinical Excellence (NICE) invited the manufacturer of omalizumab (Novartis Pharmaceuticals UK) to submit evidence for the clinical and cost effectiveness of this drug for patients with severe...
Persistent link: https://www.econbiz.de/10011001757
A two-stage stochastic mathematical programming formulation has been developed to optimally allocate resources within and between healthcare programmes when there is an exogenous budget and the parameters of the healthcare models are variable and uncertain. This formulation solves the optimal...
Persistent link: https://www.econbiz.de/10005347534
The National Institute for Health and Clinical Excellence (NICE) invited the manufacturer of dronedarone (Multaq, Sanofi-Aventis Limited, UK) to submit evidence on the clinical and cost effectiveness of the anti-arrhythmic drug (AAD) for the treatment of atrial fibrillation (AF) and atrial...
Persistent link: https://www.econbiz.de/10010614373
The allocation problem in health care can be characterised as a mathematical programming problem but attempts to incorporate uncertainty in costs and effect have suffered from important limitations. A two-stage stochastic mathematical programming formulation is developed and applied to a...
Persistent link: https://www.econbiz.de/10008499142
Following a licence extension to include those aged 6-11 years, the National Institute for Health and Clinical Excellence (NICE) invited the manufacturer of omalizumab (Novartis Pharmaceuticals UK) to submit evidence for the clinical and cost effectiveness of this drug for patients with severe...
Persistent link: https://www.econbiz.de/10010579449